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Materials and Methods: We evaluated 22 women diagnosed with 
cervical cancer that had undergone pre and post treatment FDG-PET. 
Patients were treated with standard doses of concomitant chemo-
radiotherapy in our department from 2005-2012. Using deformable 
image registration and dose remapping technology (Velocity AI 
software), we delineated total (BMtot) and active BM (BMact) volumes 
receiving >1 Gy on the radiotherapy planning image sets, combining 
dose matrix data of treatment planning and PET images. Minimum, 
mean, and maximum SUVs and dose maximum (Dmax), mean, volume 
receiving 10 Gy (V10), V20, V30, V40 were computed on BMtot and 
BMact separately using initial and after treatment (response) PET’s, 
respectively. Hemograms before the treatment start, during the acute 
toxicity period (nadirs), 3 months after the treatment (response PET), 
and at the late follow-up period were obtained. 
Results: Mean volumetric BMact/BMtot ratio was 45.6%. In two-tailed 
Student’s t-Test, initial /response SUV rates were 73% and 60% for 
BMtot and BMact, respectively; with significant reduction (p < 0.001). 
In two-tailed sign test, all dosimetric parameters of BMtot and BMact 
were different (p < 0.001) except Dmax. Significant correlations were 
observed in pairwise analysis between inital SUV values and acute 
hematologic nadirs; response SUV measurements and response PET 
hematological values, respectively (p < 0.05). Effects of varied 
parameters were found on acute and response PET hemograms in 
multiple logistic regression analysis but not on the hemograms of the 
last follow-ups. 
Conclusions: Our novel method to delineate and measure active bone 
marrow in radiation oncology combining deformable registration, 
metabolic imaging, and dose remapping can allow creating new 
models to predict both acute and late toxicity. Further analysis of this 
approach will be done with a larger cohort.  
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Purpose/Objective: To evaluate the patterns of nodal failure 
(recurrences and persistent disease) in patients with locally advanced 
cervix cancer. 
Materials and Methods: EMBRACE is a multicenter prospective 
observational study to investigate the impact of MRI guided 3D 
brachytherapy on outcome in locally advanced cervix cancer. 
Treatment consists of a combination of external beam radiotherapy 
(EBRT), MRI guided brachytherapy and concomitant chemotherapy. 
According to the protocol all elective pelvic nodal regions are treated 
with 45-50 Gy EBRT and macroscopic pathological nodes are boosted 
to about 60 Gy. Elective para-aortic irradiation to L1-L2 is given if 
pathological nodes are found at the level of common iliac or higher. 
This study includes 493 consecutive patients FIGO stage IB to IVB (with 
nodal involvement up to L2), included from November 2008 till July 
2011 with a median follow-up of 14 months. Cox regression analysis 
was performed comparing patients with and without nodal 
recurrences.  
Results: Lymph node involvement at time of diagnosis was present in 
235 patients (50%). 215 patients (46%) had suspicious nodes in the 
lower iliac (external/internal iliac), 70 patients (15%) in the common 
iliac and 39 patients (8.4%) in the para-aortic region. The highest level 
of verification was radiology in 38%, PET-CT in 35% and pathology in 
27%. The 2-year actuarial rate for nodal failure was 11%. Nodal failure 
occurred in 56 patients, 7 of which had persistent nodal disease, with 
median time to detection being 9 months (range 1-34 months). More 
than one lymph node region was involved in 45% of the patients. Nodal 
failures were present in 15% of node positive patients and 8% of node 
negative patients. Most nodal failures were located in the para-aortic 
region (n=35, 62%), with 77% of them being outside the radiation 
fields. Nodal failures in the lower iliac and the common iliac region 
occurred in respectively 39% (n=22) and 27% (n=15), all of which inside 
the elective treatment fields. In multivariate analysis the only 
predictive factors for nodal failure were tumour diameter ≥ 5 cm 
(p=.03) and presence of lymph nodes at time of diagnosis (especially if 
PET-CT positive or pathologically proven) (p=.003).  
 
  
Conclusions: Suspicious or proven nodal disease at time of diagnosis 
was seen in 50% of the patients with locally advanced cervix cancer. 
Tumour diameter ≥ 5 cm and nodal disease at time of diagnosis were 
predictive factors for nodal failure. Nodal disease at time of diagnosis 
was located mostly in the lower iliac, whereas nodal failures were 
located mostly in the para-aortic region. The majority of para-aortic 
recurrences occurred outside the radiation field, suggesting a deficit 
in treated volume due to suboptimal detection of clinical disease. 
Future work will focus on improved detection of nodal disease at time 
of diagnosis and on a more detailed analysis of dose volume effects 
with longer FU. 
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Purpose/Objective: Whole-pelvis concurrent chemoradiation (WP-
CCRT) is the standard treatment option for patients with locally 
advanced cervical cancer. However WP-CCRT could not decrease the 
para-aortic nodal recurrences, so our aim was to evaluate whether 
extended field concurrent chemoradiation (EF-CCRT) leads to results 
better to those obtained by standard WP-CCRT in locally advanced 
cervical cancer with radiologic negative para-aortic lymph nodes 
(PALN). 
Materials and Methods: Patient eligibility included histopathologically 
proven squamous cell carcinoma, adenocarcinoma or adeno-squamous 
cell carcinoma; radiologic negative PALN locally advanced cervical 
cancer stages IIB-IVA with normal hematologic, renal,and liver 
functions. Between July 2007 and April 2008, 82 were 
accrued.Patients were randomly assigned to WP-CCRT (40 patients) 
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and EF-CCRT (42 patients) followed by high dose rate brachytherapy. 
Data regarding the safety profile, response rates and occurrence of 
local, para-aortic or distant failure were recorded. 
Results: Witha median follow-up time of 5 years (range, 4-5.5), EF-
CCRT ( 38 patients) was associated with better 5-year disease-free 
survival of 80.3% compared with 69.1% in 36 patients treated with WP-
CCRT (p = 0.04). The PALN control rates were 97.1% and 82.1% in EF-
CCRT and WP-CCRT respectively (p = 0.03) and distant control rates 
were 94.7% in EF-CCRT and 80.6% in WP-CCRT (p = 0.02). The 5-year 
overall survival rates were 72.4% for EF-CCRT and 60.4% for WP-CCRT 
(p = 0.04). No difference in acute toxicity profile was seen in both 
groups and during a median follow up of 60 months, one patient 
(2.6%) in EF-CCRT group experienced intestinal obstruction.  
Conclusions: Prophylactic EF-CCRT showed better para-aortic nodal, 
distant control, disease-free survival, and overall survival rates as 
those of WP-CCRT with acceptable toxicity in patients with radiologic 
negative PALN locally advanced cervical cancer. 
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Purpose/Objective: Diffusion Weighted MRI (DW-MRI) is used for 
diagnostic cancer imaging and may have value for monitoring of tumor 
response to radiotherapy (RT). In this study, DW-MRI was evaluated as 
a non-invasive biomarker for prediction of local failure in RT of locally 
advanced cervical cancer. 
Materials and Methods: 52 patients were treated with 45-50Gy whole 
pelvis external beam RT (EBRT) and 2 fractions of brachytherapy (BT). 
Patients underwent MRI examination 3 times during treatment with 
the BT applicator in situ: 1) a preplanning MRI (BT0) one week prior to 
first BT, 2) at time of first BT and 3) at time of second BT (BT2) one 
week after first BT. Dose-planning for BT was based on T2-weighted 
MRI following the GEC-ESTRO guidelines. DW-MRI (b=0, 600, 1.000 
s/mm2) was included in all three MRIs using a 1.5T MRI. Median 
follow-up time from start of treatment was 24 month (min/max: 6/46 
month). Blinded visual assessment of signal intensities on DW-MRI, 
b=1.000 s/mm2 at time of BT0 was evaluated for hyper-intensity at 
tumor site and was found in 22/52 patients (table 1).Images of 
Apparent Diffusion Coefficients (ADC) were calculated for the 
22patients. The relationship between local failure and ADC, change in 
ADC and volumes was investigated. 
Results: There was asignificant correlation between local failure 
(Fischer’s exact test p=0.021) and presence of hyper-intense signal on 
DW-MR images at b=1.000 s/mm2 at time of BT0 (Table 1). The ADC 
for DWI ROI at BT0 in patients with local control (1.21±0.19 x10-3 
mm2/s) compared to failures (1.31±0.24 x10-3 mm2/s) was not 
significant(p=0.21). There was no significant change in ADC from BT0 
to BT2 (p = 0.44).There was a significant decrease in the volume of 
the DWI ROI for both patients with local control (VBT0 = 5.06±4.72 
cm3 to VBT2= 1.51±1.36 cm3) (p = 0.016) and failures (VBT0= 
7.54±5.02 cm3 to VBT2 = 4.12±3.12 cm3) (p =0.003). The mean DWI 
ROI volume at time of BT2 was significantly larger (p=0.006)in patients 
with failures as compared to those with local control.  
 
  
Conclusions: The presence of hyper-intense tumor signal at highly 
diffusion sensitive images (b = 1.000s/mm2) at time of BT seems to be 
a strong indicator for increased risk of persistent local disease or local 
recurrence. However, the qualitative and subjective nature of the 
visual evaluation of hyper-intense signal at DW-MR images is an issue 
that should be addressed in future work. At this time of treatment the 
ADC appears stable before and after the BT fraction and it was not 
possible to use the ADC to differentiate between responders and non-
responders. The study shows that the tumor delineated by the DWI 
ROI decreases during treatment although the ADC value did not 
change. This study indicates that DW-MRI may be of value for 
monitoring RT-treatment and predicting local failure already during 
treatment.  
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Purpose/Objective: This study aims to determine candidate genes 
and chromosomal imbalances capable of predicting metastasis 
occurrence in a homogenous population of patients with rectal 
cancer. 
Materials and Methods: Fresh frozen tumor tissues from 80 patients 
with rectal cancer were analyzed using Affymetrix HG-U133 Plus 2.0 
gene expression arrays and high-resolution Illumina single nucleotide 
polymorphism (SNP) arrays. Median follow-up was 102 (1-146) months. 
Endpoints of the study were metastasis-free survival (MFS) and 
cancer-specific survival (CSS). The prognostic value of two validated 
colon gene expression signatures was also tested in this cohort. 
Results: We were unable to derive a significant predictor of prognosis 
based on gene expression, since only a few genes were significantly 
associated with MFS or CSS after multiple testing corrections. In 
contrast, deletions of 8p and 1p36-35 correlated with worse MFS (P = 
0.005 and P = 0.01, respectively) and CSS (P = 0.001 and P = 0.01, 
respectively). Multivariate analysis identified -8p as an independent 
prognostic factor for MFS (P = 0.04) and CSS (P = 0.003). A genomic 
signature of colon cancer was not significantly associated with 
prognosis, whereas another one significantly predicted MFS in T3 
tumors (P = 0.04). 
Conclusions: This study shows for the first time in rectal cancer an 
independent correlation of -8p with MFS and CSS. Specific prognostic 
factors may apply to rectal cancer, justifying the need for 
homogeneous rectal cancer samples in prognostic studies.  
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Purpose/Objective: Target volume definitions for radiotherapy in 
pancreatic ductal adenocarcinoma (PDAC) vary substantially. Some 
groups aim to treat only the primary tumour whereas others include 
elective lymph nodes (eLN’s). ELN’s close to the primary tumour are 
often included unintentionally within the treatment volume, 
depending on the respective philosophies. We aimed to measure the 
percentages of anatomical coverage of the eLN’s comparing four 
different guidelines. 
Materials and Methods: PTVs were contoured using planning-CT’s of 
eleven patients with PDAC based on the Oxford, RTOG, Michigan and 
SCALOP guidelines. CTVs included the peripancreatic, paraaortic, 
paracaval, celiac trunk, superior mesenteric and portal vein lymph 
node areas. Volumetric comparisons of coverage of all eLN regions 
were conducted to illustrate the differences between the 4 contouring 
strategies. 
Results: Significant differences in PTV sizes were observed in the 
following order: RTOG > Oxford > SCALOP > Michigan (620, 450, 230, 
160 ccm, respectively). A large variation of eLN coverage was found 
for the respective subregions according to the respective guidelines. 
The eLN areas of highest risk, i.e. posterior peripancreatic nodes were 
covered best in Oxford and RTOG definitions. Much of the additional 
volume of the latter two compared to Michigan and SCALOP was 
related to paraaortic and portal venous eLNs. 
